Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Posted By Dr. Ari Weitzner On April 17, 2009 @ 7:32 am In Glaucoma,Industry News | Comments Disabled

Santen Pharmaceutical of Japan announced earlier this week that it had signed a worldwide licensing agreement granting Merck exclusive rights to market tafluprost in North America (among other territories).

Tafluprost is a prostaglandin analogue for reduction of intraocular pressure in primary open angle glaucoma and ocular hypertension. Tafluprost is currently an investigational compound in the United States. If Tafluprost is approved in the United States, Santen will have the option to co-promote the product in the United States.

Read ^[1] the full press release.

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/00877-santen-and-merck-sign-licensing-agreement-for-tafluprost-treatment-for-glaucoma-and-ocular-hypertension/

URLs in this post:

[1] Read: http://www.santen.com/news/20090415.pdf

Click here to print.